These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 35768871)

  • 21. Is the Androgen Receptor a Viable Target in Triple Negative Breast Cancer in 5 Years?
    Sharifi MN; O'Regan RM; Wisinski KB
    Clin Breast Cancer; 2023 Dec; 23(8):813-824. PubMed ID: 37419745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer.
    Thakkar A; Wang B; Picon-Ruiz M; Buchwald P; Ince TA
    Breast Cancer Res Treat; 2016 May; 157(1):77-90. PubMed ID: 27120467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RUNX1 Is Regulated by Androgen Receptor to Promote Cancer Stem Markers and Chemotherapy Resistance in Triple Negative Breast Cancer.
    Fernández NB; Sosa SM; Roberts JT; Recouvreux MS; Rocha-Viegas L; Christenson JL; Spoelstra NS; Couto FL; Raimondi AR; Richer JK; Rubinstein N
    Cells; 2023 Jan; 12(3):. PubMed ID: 36766786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
    Luo J; Jin J; Yang F; Sun Z; Zhang W; Shi Y; Xu J; Guan X
    Int J Biol Sci; 2016; 12(12):1500-1510. PubMed ID: 27994514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR
    Lehmann BD; Abramson VG; Sanders ME; Mayer EL; Haddad TC; Nanda R; Van Poznak C; Storniolo AM; Nangia JR; Gonzalez-Ericsson PI; Sanchez V; Johnson KN; Abramson RG; Chen SC; Shyr Y; Arteaga CL; Wolff AC; Pietenpol JA;
    Clin Cancer Res; 2020 May; 26(9):2111-2123. PubMed ID: 31822498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Androgen Receptor Promotes Cellular Proliferation by Suppression of G-Protein Coupled Estrogen Receptor Signaling in Triple-Negative Breast Cancer.
    Shen Y; Yang F; Zhang W; Song W; Liu Y; Guan X
    Cell Physiol Biochem; 2017; 43(5):2047-2061. PubMed ID: 29059676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogen receptor beta suppresses the androgen receptor oncogenic effects in triple-negative breast cancer.
    Xu F; Xu K; Fan L; Li X; Liu Y; Yang F; Zhu C; Guan X
    Chin Med J (Engl); 2024 Feb; 137(3):338-349. PubMed ID: 38105538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HC-1119, a deuterated Enzalutamide, inhibits Migration, Invasion and Metastasis of the AR-positive triple-negative breast Cancer cells.
    Wu X; Feng W; Yang M; Liu X; Gao M; Li X; Gan L; He T
    Mol Biol Rep; 2022 Oct; 49(10):9231-9240. PubMed ID: 35960413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the androgen receptor in triple-negative breast cancer.
    Gucalp A; Traina TA
    Curr Probl Cancer; 2016; 40(2-4):141-150. PubMed ID: 27816190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression.
    Christenson JL; Butterfield KT; Spoelstra NS; Norris JD; Josan JS; Pollock JA; McDonnell DP; Katzenellenbogen BS; Katzenellenbogen JA; Richer JK
    Horm Cancer; 2017 Apr; 8(2):69-77. PubMed ID: 28194662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
    Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
    Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of a targetable JAK-STAT enriched androgen receptor and androgen receptor splice variant positive triple-negative breast cancer subtype.
    Asemota S; Effah W; Young KL; Holt J; Cripe L; Ponnusamy S; Thiyagarajan T; Hwang DJ; He Y; Mcnamara K; Johnson D; Wang Y; Grimes B; Khosrosereshki Y; Hollingsworth TJ; Fleming MD; Pritchard FE; Hendrix A; Khan F; Fan M; Makowski L; Yin Z; Sasano H; Hayes DN; Pfeffer LM; Miller DD; Narayanan R
    Cell Rep; 2023 Dec; 42(12):113461. PubMed ID: 37979170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of AR antagonist combined with PARP1 inhibitor on sporadic triple-negative breast cancer bearing AR expression and methylation-mediated BRCA1 dysfunction.
    Sang M; Meng L; Ma C; Liu S; Sang M; Chang S; Liu F; Lian Y; Geng C
    Biomed Pharmacother; 2019 Mar; 111():169-177. PubMed ID: 30580238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgens Induce Invasiveness of Triple Negative Breast Cancer Cells Through AR/Src/PI3-K Complex Assembly.
    Giovannelli P; Di Donato M; Auricchio F; Castoria G; Migliaccio A
    Sci Rep; 2019 Mar; 9(1):4490. PubMed ID: 30872694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signaling.
    Narayanan R; Ahn S; Cheney MD; Yepuru M; Miller DD; Steiner MS; Dalton JT
    PLoS One; 2014; 9(7):e103202. PubMed ID: 25072326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness".
    Lim B; Seth S; Yam C; Huo L; Fujii T; Lee J; Bassett R; Nasser S; Ravenberg L; White J; Clayborn A; Guerra G; Litton JK; Damodaran S; Layman R; Valero V; Tripathy D; Lewis M; Dobrolecki LE; Lei J; Candelaria R; Arun B; Rauch G; Zhao L; Zhang J; Ding Q; Symmans WF; Chang JT; Thompson AM; Moulder SL; Ueno NT
    Cell Rep Med; 2024 Jun; 5(6):101595. PubMed ID: 38838676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. JAK2 regulates paclitaxel resistance in triple negative breast cancers.
    Han J; Yun J; Quan M; Kang W; Jung JG; Heo W; Li S; Lee KJ; Son HY; Kim JH; Choi J; Noh DY; Na D; Ryu HS; Lee C; Kim JI; Moon HG
    J Mol Med (Berl); 2021 Dec; 99(12):1783-1795. PubMed ID: 34626199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Positive Feedback Loop Between TGFβ and Androgen Receptor Supports Triple-negative Breast Cancer Anoikis Resistance.
    Rosas E; Roberts JT; O'Neill KI; Christenson JL; Williams MM; Hanamura T; Spoelstra NS; Vahrenkamp JM; Gertz J; Richer JK
    Endocrinology; 2021 Feb; 162(2):. PubMed ID: 33294922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.